References
- Eliopoulos GM, Moellering RC. Antibiotics in laboratory medicine: Williams; 1996.
- Baillie GS, Douglas II. Candida biofilms and their susceptiblity to antifungal agents. Methods Enzymol. 1999; 310: 644–56.
- Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum M. Biofilm formation by the fungal pathogen Can dida albicans: development, architecture, and drug resistance. J Bacteriol. 2001; 183: 5385–94.
- Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Guidelines for treatment of Candidiasis. Clin Infect Dis. 2004; 38: 161–89.
- Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, et al. A randomized and blinded multicenter trial of high-dose Fluconazole plus placebo versus Fluconazole plus Amphotericin B as therapy for Candidemia and its conse-quences in nonneutropenic subjects. Clin Infect Dis. 2003; 36: 1221–8.
- Saral R. Candida and Aspergillus infections in immuno-compromised patients: an overview. Rev Infect Dis. 1991; 13: 487–92.
- Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive Aspergillosis. Clin Infect Dis. 2004; 39: 797–802.
- Woyke T, Berens ME, Hoelzinger DB, Pettit GR, Winkelmann G, Pettit RK. Differential gene expression in Auristatin PHE-treated Cryptococcus neoformans. Antimicrob Agents Chemother. 2004; 48: 561–7.
- Woyke T, Pettit GR, Winkelmann G, Pettit RK. In vitro activities and postantifungal effects of the potent Dolastatin 10 derivative Auristatin PHE. Antimicrob Agents Chemother. 2001; 45: 3580–4.
- Woyke T, Roberson RW, Pettit GR, Winkelmann G, Pettit RK. Effect of Auristatin PHE on microtuble integrity and nuclear localization in Cryptococcus neoformans. Antimicrob Agents Chemother. 2002; 46: 3802–8.
- Pettit RK, Hamel E, Pinard V, Roberson RW, Hazen KC, Pettit GR, et al. Antifungal and cancer cell growth inhibitory activities of 1-(3',4',54rimethoxyphenyl)-2-nitro-eth-ylene. Mycoses. 2002; 45: 65–74.
- CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard - M27-A2. Wayne, PA, USA: CLSI; 2002.
- CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium-Forming Filamentous Fungi: Approved Standard M38-A. Wayne, PA, USA: CLSI; 2002.
- Pettit GR, Srirangam JK, U.S. patent 5,780,588. July 1998.
- Pettit GR, Srirangam JK, Barkoczy J, Williams MD, Boyd MR, Hamel E, et al. Antineoplastic agents 365. Dolistatin 10 SAR probes. Anticancer Drug Dis. 1998; 13: 243–77.
- Spath E. Uber die anhalonium-alkaloide. Monatshefte Chemie. 1919; 40: 129–54.
- Pettit RK, Pettit GR, Hazen KC. Specific activities of Dolastatin 10 and peptide derivatives against Cryptococcus neoformans. Antimicrob Agents Chemother. 1998; 42: 2961–5.
- Johnson MD, MacDougall C, L. O-Z, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob Agents Chemother. 2004; 48: 693–715.